Antibody conjugates have rapidly change into a giant a part of AstraZeneca's gross sales progress. The drugmaker is taking steps to make sure it has the manufacturing capability to fulfill market demand for these most cancers medicine, asserting plans for a $1.5 billion manufacturing website in Singapore to develop international provide of ADC medicine to help.

Development of the ADC manufacturing facility will obtain help from the Singapore Financial Improvement Board, AstraZeneca mentioned on Monday. The corporate expects to start design and building of the power by the tip of this yr. Development of a brand new drug manufacturing website and acquiring regulatory approvals for industrial manufacturing can take a number of years. AstraZeneca goals to open its new website for ADC manufacturing in 2029.

An ADC is a most cancers remedy that consists of three elements: a focused antibody, a chemotherapy payload, and a chemical linker that connects the 2. At the moment, AstraZeneca's ADC manufacturing is dealt with at a number of websites answerable for steps akin to antibody manufacturing, synthesis of the chemotherapy and chemical linker, and conjugation of the drug and linker to the antibody. The ultimate step is filling and ending manufacturing, the place bottles are stuffed and packaged for distribution.

AstraZeneca says the deliberate manufacturing unit in Singapore would be the first end-to-end ADC manufacturing website protecting all manufacturing steps at a industrial scale. In a ready assertion, AstraZeneca CEO Pascal Soriot mentioned Singapore is without doubt one of the most engaging international locations on the planet for funding as a consequence of its repute for excellence in complicated manufacturing.

AstraZeneca's ADC vary is led by Enhertu, a remedy developed in collaboration with Daiichi Sankyo. The drug acquired its first FDA approval for HER2-positive breast most cancers in 2019. Its permitted use in that kind of most cancers now spans greater than 55 international locations. The drug has additionally earned further approvals for abdomen most cancers, HER2-low breast most cancers and lung most cancers.

Enhertu reached blockbuster standing in 2023, bringing in $1.28 billion in income, a 113% enhance over the earlier yr's income, in keeping with AstraZeneca's monetary studies. The drug continues to seek out increasingly more purposes. Final month, the FDA permitted Enhertu for the remedy of strong tumors that specific HER2, no matter the kind of most cancers or the place within the physique the illness began. Along with Enhertu, AstraZeneca says its pipeline contains six wholly owned ADCs in varied phases of medical testing, in addition to extra ADCs in preclinical improvement.

The ADC website in Singapore is AstraZeneca's second main manufacturing announcement this yr. In February, the drugmaker introduced a $300 million funding in cell remedy manufacturing within the US. The brand new location in Rockville, Maryland, will produce cell therapies for medical trials. It should even have the capability to deal with future industrial manufacturing of AstraZeneca cell therapies.

Photograph: Christopher Furlong, Getty Photos